KMB

Business Context and Reporting Period

Company: Kimberly-Clark Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: A multinational consumer goods company organized into four reportable segments: Personal Care, Consumer Tissue, K-C Professional & Other, and Health Care. The company manufactures and markets disposable diapers, tissue products, professional safety products, and health care supplies.

Key Financial Metrics

All figures in millions of dollars, except per share data.

Margins (Nine Months 2009):
- Gross Margin: 33.6%
- Operating Margin: 14.9%
- Net Margin (Attributable to K-C): 9.8%

Material Changes vs. Prior Period

• Revenue: Net sales decreased 1.7% in Q3 2009 and 4.6% YTD 2009 compared to the prior year. Declines were driven by unfavorable currency effects (approx. 5% in Q3, 8% YTD) and lower sales volumes, partially offset by higher net selling prices.
• Profitability: Operating profit increased 42.8% in Q3 and 9.6% YTD. This growth was primarily driven by significant input cost deflation (approx. $270 million in Q3), cost savings from the FORCE program, and higher selling prices.
• Segment Performance:
  • Health Care: Strongest performer with operating profit up 254.5% in Q3, driven by volume growth (including H1N1-related demand for masks) and cost deflation.
  • Consumer Tissue: Operating profit up 74.4% in Q3 due to cost deflation and price increases, despite volume declines.
  • Personal Care: Operating profit up 15.6% in Q3; sales volumes fell in North America but rose in Europe and emerging markets.
• Currency Impact: Unfavorable currency effects reduced operating profit by approximately $75 million in Q3. Significant currency transaction losses ($13 million in Q3, $109 million YTD) were recorded, largely due to Venezuelan currency restrictions.
• Pension Contributions: Cash contributions to pension trusts increased significantly to $718 million YTD 2009 compared to $67 million in the prior year.

Guidance, Outlook, and Risks

• Updated Guidance: Management raised the full-year 2009 earnings per share estimate to a range of $4.50 to $4.60, up from the previous $4.10 to $4.25. This reflects increased cost savings, better organic sales growth, and currency recovery.
• Capital Allocation:
  • Capital spending for the first nine months was $563 million; full-year target remains $800 to $850 million.
  • Acquired Jackson Products, Inc. for ~$155 million in Q2.
  • Announced intent to acquire I-Flow Corporation for ~$276 million (expected close before year-end).
  • No share repurchases under the $5 billion program in Q3 2009.
• Organization Optimization: Announced a plan to reduce the worldwide salaried workforce by ~1,600 positions. Cumulative pretax charges are estimated at $130 to $140 million by year-end. $122 million in charges were recorded YTD.
• Risks and Contingencies:
  • Currency: Ongoing volatility and restrictions (specifically in Venezuela) impacting translation and transaction results.
  • Raw Materials: Exposure to fluctuations in fiber, polymer resins, and energy costs, though currently benefiting from deflation.
  • Accounting Changes: Adopted new FASB guidance regarding noncontrolling interests and variable interest entities (VIEs), though no material financial effect was noted.

Investor Verification Checklist

• Currency Sensitivity: Verify the magnitude of currency headwinds in Europe and emerging markets and the sustainability of the "recovery" assumptions in the updated guidance.
• Cost Deflation Sustainability: Assess whether the ~$270 million in input cost savings seen in Q3 is a one-time benefit or a structural shift in raw material pricing.
• Pension Obligations: Review the long-term impact of the $718 million pension contribution and the "freeze" of the U.S. defined benefit plan on future cash flows.
• Acquisition Integration: Monitor the integration and financial impact of the Jackson Products and pending I-Flow acquisitions.
• Restructuring Execution: Track the progress of the 1,600 job reduction plan and the realization of associated cost savings against the $130-$140 million charge estimate.